<DOC>
	<DOCNO>NCT01229865</DOCNO>
	<brief_summary>The purpose study examine safety evaluate response VB-111 DTC .</brief_summary>
	<brief_title>Safety Efficacy VB-111 Subjects With Advanced Differentiated Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<criteria>1 . Histologically cytologically confirm advanced DTC ( papillary , follicular , Hurthle cell ) ; 2 . Absence sensitivity therapeutic radioiodine ; 3 . Measurable disease , define least one nonbony lesion accurately measure least one dimension confirm spiral CT scan 4 . Life expectancy &gt; 3 month ; ECOG performance status ( PS ) 0 , 1 , 2 ; Karnofsky performance status ≥60 % ; 5 . Subjects normal/acceptable hematological profile 6 . Subjects adequate renal function 1 . Presence follow : Radiotherapy chemotherapy &lt; 4 week prior baseline visit ; ( Concurrent and/or prior therapy octreotide allow , provide tumor progression therapy demonstrate ; Concurrent and/or prior therapy biphosphonates allow ) Radiotherapy ≥25 % bone marrow ; 2 . Major surgery &lt; 4 week prior baseline visit ; 3 . Any ongoing investigational agent within 4 week dose ; 4 . Subjects suffer acute cardiac event within last 12 month , include myocardial infarction , cardiac arrythmia , admission unstable angina , cardiac angioplasty , stenting ; 5 . QTc prolongation ( define QTc interval ≥500 msec ) significant ECG abnormality ( e.g . frequent ventricular ectopy , evidence ongoing myocardial ischemia ) ; 6 . Subjects active vascular disease , either myocardial peripheral ; 7 . Subjects proliferative and/or vascular retinopathy ; 8 . Subjects know active liver disease ( alcoholic , drug/toxin induce , genetic , autoimmune ) relate tumor metastasis ; 9 . Subjects know CNS metastatic disease ( Exception : Subjects treat CNS metastasis stable radiographic examination &gt; 6 month definitive therapy administer , eligible ) ; 10 . Subjects test positive one follow virus : HIV , HBV HCV ; 11 . Any following condition : Serious nonhealing wound , ulcer , bone fracture ; History abdominal fistula , gastrointestinal perforation , active diverticulitis , intraabdominal abscess gastrointestinal tract bleed within 6 month dose ; Any history cerebrovascular accident ( CVA ) within 6 month dose ; Current use therapeutic warfarin ( Note : Low molecular weight heparin prophylactic lowdose warfarin [ INR &lt; 1.2 X ULN ] permit ) ; History bleed disorder , include subject hemophilia , disseminate intravascular coagulation ( DIC ) , abnormality coagulation potentially predisposing subject bleed ; Poorly control depression anxiety disorder , recent ( within previous 6 month ) suicidal ideation ; 12 . Subjects ongoing requirement immunosuppressive treatment , include use glucocorticoid cyclosporin , history chronic use medication within last 4 week dose ; 13 . Uncontrolled intercurrent illness include , limited ongoing active infection , psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>